NDAORALTABLETPriority Review
Approved
Sep 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
VIZIMPRO (dacomitinib) by Pfizer. Approved for non-small cell lung cancer, egfr-mutant non-small cell lung cancer. First approved in 2018.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIZIMPRO (dacomitinib) is an oral small-molecule tyrosine kinase inhibitor approved in 2018 for non-small cell lung cancer and evaluated across multiple hematologic and solid tumors including breast, pancreatic, prostate cancers and various leukemias and lymphomas. The drug inhibits EGFR and HER2 family receptors to block tumor cell proliferation and survival signaling.
$3.0MPart D
Peak6.4 years to LOEVIZIMPRO is in peak lifecycle with modest Medicare uptake ($3M Part D spend), indicating a mature but niche product with stable team investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on VIZIMPRO at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.